

GLAXOSMITHKLINE PLC

Form 6-K

February 12, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 12 February 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley
- b) Position/status Chief Executive Officer
- c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

- c) Price(s) and volume(s) 

Price(s)	Volume(s)
£15.5433	8 (partnership shares)
£15.5433	8 (matching shares)

Aggregated information

- d) Aggregated volume 16 Ordinary Shares  
Price £15.5433
- e) Date of the transaction 2019-02-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
- b) Position/status President, Global Vaccines

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- c) Initial notification/amendment Initial notification  
 Details of the issuer, emission allowance market participant, auction  
 2. platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s)              |
|----------|------------------------|
| £15.5433 | 8 (partnership shares) |
| £15.5433 | 8 (matching shares)    |
- Aggregated information
- d) Aggregated volume 16 Ordinary Shares  
 Price £15.5433
- e) Date of the transaction 2019-02-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S Dingemans  
 b) Position/status Chief Financial Officer

- c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

	Ordinary shares of 25 pence each (‘Ordinary Shares’)
a) Description of the financial instrument	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s)    Volume(s) £15.5433    8 (partnership shares) £15.5433    8 (matching shares)
Aggregated information	
d) Aggregated volume Price	16 Ordinary Shares £15.5433
e) Date of the transaction	2019-02-11
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them (‘PCA’)

a) Name	Mr N Hirons
b) Position/status	SVP, Global Ethics & Compliance
c) Initial notification/amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each (‘Ordinary Shares’) ISIN: GB0009252882
--	---

b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.5433	8 (partnership shares) £15.5433 8 (matching shares)
Aggregated information		
d) Aggregated volume	16 Ordinary Shares	
Price	£15.5433	
e) Date of the transaction	2019-02-11	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr L Miels
b) Position/status	President, Global Pharmaceuticals
c) Initial notification/amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.5433	8 (partnership shares) £15.5433 8 (matching shares)

## Aggregated information

- d) Aggregated volume                    16 Ordinary Shares  
Price                                        £15.5433
- e) Date of the transaction                2019-02-11
- f) Place of the transaction                London Stock Exchange (XLON)

## 1. Details of PDMR/person closely associated with them ('PCA')

- a) Name                                        Mr D S Redfern
- b) Position/status                            Chief Strategy Officer
- c) Initial notification/amendment        Initial notification

## 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name                                        GlaxoSmithKline plc
- b) LEI    5493000HZTVUYLO1D793

## 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument    Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction                Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s)                    Price(s)    Volume(s)  
£15.5433    8 (partnership shares)  
£15.5433    8 (matching shares)

## Aggregated information

- d) Aggregated volume                    16 Ordinary Shares  
Price                                        £15.5433
- e) Date of the transaction                2019-02-11
- f) Place of the transaction                London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R Simard
- b) Position/status President, Pharma Supply Chain
- c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

- c) Price(s) and volume(s) 

Price(s)	Volume(s)
£15.5433	8 (partnership shares)
£15.5433	8 (matching shares)

Aggregated information

- d) Aggregated volume 16 Ordinary Shares  
Price £15.5433
- e) Date of the transaction 2019-02-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

b) Position/status SVP, Human Resources

c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.5433	8 (partnership shares)
£15.5433	8 (matching shares)

Aggregated information

d) Aggregated volume 16 Ordinary Shares  
Price £15.5433

e) Date of the transaction 2019-02-11

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson

b) Position/status President, Global Affairs

c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc



- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s)              |
|----------|------------------------|
| £15.5433 | 8 (partnership shares) |
| £15.5433 | 8 (matching shares)    |
- Aggregated information
- d) Aggregated volume 16 Ordinary Shares  
Price £15.5433
- e) Date of the transaction 2019-02-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument

Ordinary shares of 25 pence each  
(‘Ordinary Shares’)  
ISIN: GB0009252882

b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £15.5433 8 (partnership shares) £15.5433 8 (matching shares)
Aggregated information	
d) Aggregated volume Price	16 Ordinary Shares £15.5433
e) Date of the transaction	2019-02-11
f) Place of the transaction	London Stock Exchange (XLON)

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GlaxoSmithKline plc  
(Registrant)

Date: February 12, 2019

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorized Signatory for and on  
behalf of GlaxoSmithKline plc